QC
RCKT icon

Quadrature Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

Quadrature Capital’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-65,376
Closed -$229K – 1766
2025
Q4 		$229K Sell
65,376
-20,137
-24% -$68.9K ﹤0.01% 934
2025
Q3 		$279K Sell
85,513
-7,079
-8% -$22.3K ﹤0.01% 694
2025
Q2 		$226K Buy
+92,592
New +$469K ﹤0.01% 779

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Quadrature Capital's RCKT Position: Q1 2026 in Review

Quadrature Capital sold out of Rocket Pharmaceuticals (RCKT) in Q1 2026, closing a stake of 65,376 shares — an estimated $229K sold.

Quadrature Capital first reported a position in RCKT in Q2 2025 and held it in 3 quarters. The position peaked at $279K in Q3 2025. 199 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Quadrature Capital reported no remaining Rocket Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 65,376 Rocket Pharmaceuticals shares in Q1 2026, an estimated $229K.
  • Quadrature Capital first reported a position in Rocket Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Quadrature Capital's Rocket Pharmaceuticals position peaked at $279K in Q3 2025.
  • 199 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.